Skip to main content

Table 2 Delayed type hypersensitivity response to PPD during first cycle of study a

From: Thalidomide Treatment Reduces Tumor Necrosis Factor α Production and Enhances Weight Gain in Patients with Pulmonary Tuberculosis

Patient Number

Skin Test Response to PPD (mm)b

Pre

Mid

Post

PPD+

   

1

26.5

20.5

24.0

3

14.0

25.0

18.5

4

19.0

16.0

20.5

5

16.5

18.0

24.5

6

14.0

12.0

16.5

7

23.5

65.0

NDc

9

18.5

14.5

21.5

11

14.5

18.0

13.0

12

19.5

26.0

17.0

13d

15.0

21.0

26.0

14d

26.5

22.0

31.0

15

16.0

18.0

10.0

16d

26.0

22.5

23.0

18d

20.0

20.5

17.0

19

15.5

18.0

16.0

20d

ND

ND

ND

21

11.0

15.5

12.0

22

22.0

19.0

17.0

23d

ND

ND

ND

25

ND

ND

ND

26

19.0

ND

ND

27

13.0

14.5

18.0

28

13.0

12.5

17.5

29d

18.0

14.0

10.0

PPD

   

2

0

9.5

0

8

0

19.5

0

10

0

12.5

0

17

0

9.0

11.5

24d

0

0

0

30

0

19.0

ND

  1. aPatients in Thailand and New York were skin tested 3× during the first cycle of study.
  2. bMean diameter of the indurated area at 48 hr after 5 u PPD administration. Diameter >10 mm is termed PPD+. cND, not done.
  3. dPatients received placebo during the first cycle of study.